Wednesday, October 20, 2010 7:29 AM
Making Translational Engineering Work: A Conversation with MIT’s Robert Langer
By By Thomas Maeder
For the past decade “translational science” and “translational medicine” have been cherished buzzwords, raising the prospect of faster, better, more seamless transfer of discoveries from bench to bedside. Too often, though, it doesn’t work. Differences in the cultures of academia and medical manufacturing, and a poor grasp of regulatory and reimbursement issues, or of what makes a bright idea into a clinically useful, commercially viable product have scuttled more than one promising innovation.
A notable exception is the prodigiously productive lab of Robert Langer at the Massachusetts Institute of Technology, which has spawned over a dozen companies, some of them successful standalones, others subsequently acquired by larger corporations, including Advanced Inhalation Research, MicroCHIPS, Alkermes, Transform Pharmaceuticals, Acusphere, Nova Pharmaceutical, Focal, Momenta, Noemorphics, EnzyMed, Reprogenesis, Sontra Medical, MnemoScience, Pulmatrix, and Pervasis Therapeut more...
|
Please log in or become a member...
To continue reading this content you must either log in become a member. If you are already a member, please log in using the form below. If you are not already a member, we invite you to join our online community. Membership is free of charge to personnel working in industry, academia, and government.
To join please click on the "Become a Member" link at the top of the page (joining takes around 1 minute and you only need to register once).
Membership benefits include free access to:
-
Industry news, feature articles, podcasts, videos and blogs
-
Weekly eNewsletter subscription
-
Resource Center including downloadable brochures, white papers, reports & media files
-
Industry events calendar
Thank you!
|
Be the first to leave a comment.
Post your comments about this article or questions for the author here